-
Portrait | 2024.05.21
Philippe Bousso: harnessing immune responses to combat cancer
Philippe Bousso, an immunologist and technophile with insatiable curiosity, is constantly tackling new challenges in his efforts to combat cancer. Like the characters in the sci-fi film Fantastic Voyage, he and his team use cutting-edge in vivo technologies to observe the ways in which the immune system wages war on cancer cells. For Philippe, creativity and innovation pave the way for new...
-
Vidéo | 2025.09.29
immune awakening
What if we could reprogram the death of cancer cells to reawaken the immune system?In this video, Philippe Bousso, a researcher at the Institut Pasteur, explains how we could:stop “silent death”add the missing piece to the alarm systemtrigger cell self-destructionLab results: tumors eliminated in two-thirds of cases.(video in french, English subtitles available)
-
News | 2024.03.27
Cancer: unexpected mechanism of action of immunotherapy revealed
Immunotherapy, now in widespread use as a treatment for cancer, continues to be a focus of research and to teach us more about the immune system. A new study by scientists at the Institut Pasteur has identified a novel mechanism of action of anti-PD-1 antibodies, a commonly used form of immunotherapy.
-
Document de presse | 2025.09.29
Blood cancer: a treatment to reprogram cancer cell death and trigger the immune system
The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a preclinical model, scientists from the Institut Pasteur and Inserm successfully stimulated an effective anti-tumor immune response by reprogramming the death of malignant B cells. They demonstrated an effective triple-therapy approach for treating forms of blood cancer such...
-
Document de presse | 2018.11.23
Cancer under pressure: visualizing the activity of the immune system on tumor development
As tumors develop, they evolve genetically. How does the immune system act when faced with tumor cells? How does it exert pressure on the genetic diversity of cancer cells? Scientists from the Institut Pasteur and Inserm used in vivo video techniques and cell-specific staining to visualize the action of immune cells in response to the proliferation of cancer cells. The findings have been...
-
News | 2019.04.01
Immune cells fighting blood cancer visualized for the first time
When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) represent a promising immunotherapy strategy, developed with the aim of tackling tumors head-on. But the occurrence of relapse in some patients remains a challenge. Scientists at the Institut Pasteur have identified the precise...
-
Document de presse | 2015.12.21
The mechanism of an AIDS vaccine candidate filmed in vivo
Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. This previously unseen footage clearly shows how the vaccine recruits the immune cells needed to destroy infected cells. These results, published in the...
-
Document de presse | 2020.03.10
Cancer: the immune system attacks tumors remotely
How does the immune system act to limit tumor development? Using in vivo imaging tools, scientists from the Institut Pasteur and Inserm described the spatiotemporal activity of tumor-infiltrating T lymphocytes, both locally and remotely. Their research was published in the journal Nature Cancer on March 9, 2020.Some cells in the immune system, like T lymphocytes, are capable of attacking cancer...
-
Document de presse | 2023.06.02
Immunotherapy for blood cancer: remote destruction of tumor cells demonstrated
The aim of immunotherapy strategies is to use cells in the patient's own immune system to destroy tumor cells. CAR T cell therapy is an immunotherapy that is effective in treating blood cancer. Around 35,000 people are affected by blood cancer each year in France, with 1.24 million cases worldwide. By closely investigating some of the immune cells generated during this therapy, known as CD4 T...
-
Document de presse | 2021.02.18
Improving immunotherapies for blood cancers: real-time exploration in the tumor
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called "immunotherapies." But how do these antibodies function within the tumor? And how can we hope to improve their efficacy? Using innovative in vivo imaging approaches, scientists from the Institut Pasteur and Inserm visualized in...